RESUMO
Cervical cancer,endometrial cancer and ovarian cancer are common gynecologic malignancies.Recently,with the younger onset age and delay of childbearing,the fertility-sparing treatment has been increasingly used.In the fertility-sparing treatment for gynecologic malignancies,we should protect the fertility of patients without increasing tumor recurrence,which requires the multidisciplinary cooperation to develop individualized treatment strategy,provide optimal reproductive guidance and finally improve the reproductive outcomes.
RESUMO
Objective To investigate the oncologic and reproductive outcomes after progestin treatment of complex endometrial hyperplasia(CEH) and grade 1 endometrial carcinoma(EC).Methods In a retrospective study, data were obtained for patients with CEH or grade 1 EC at presumed stage IA(without myometrial invasion) who wished to preserve fertility and were treated at the Peking Union Medical College Hospital, China, between January 1, 2000 and December 31, 2011.Patients had received oral medroxyprogesterone acetate(250-500 mg/d) or megestrol acetate(160-480 mg/d) for at least 6 months.Results Among 55 included patients, median age was 32 years(range 21-41 years).41(75%) achieved complete response after a median period of 6(3-24) months.Complete response was less frequent among obese than nonobese patients(4/12 [33%] vs 37/43 [86%];P=0.001).Disease recurrence was recorded in 10(24%) patients with complete response;the 5-year recurrence-freesurvival rate was 71%.Among the 33 patients who retained a desire to conceive, 17(52%) became pregnant.Conclusions Fertility-sparing management with oral progestin is effective and safe.Obesity is associated with a lower probability of long-term success.